Oleander

Oleander attenuates hepatic inflammation in a TLR4-independent manner and by favorable modulation of hepatocellular global metabolome that supports cytoprotection

Nerium oleander (NO) has been traditionally used in medicinal systems across the globe to treat liver-associated chronic metabolic diseases. This article reports[read more]

Differential Activities of the Botanical Extract PBI-05204 and Oleandrin on Innate Immune Functions under Viral Challenge Versus Inflammatory Culture Conditions

The Nerium oleander extract PBI 05204 (PBI) and its cardiac glycoside constituent oleandrin have direct[read more]

Discovery of senolytics using machine learning

Cellular senescence is a stress response involved in ageing and diverse disease processes including cancer,[read more]

The botanical drug PBI-05204, a supercritical CO2 extract of Nerium oleander, sensitizes alveolar and embryonal rhabdomyosarcoma to radiotherapy in vitro and in vivo

Treatment of rhabdomyosarcoma (RMS), the most common a soft tissue sarcoma in childhood, provides intensive[read more]

Suppression of the ‘stemness’ of glioblastoma stem cells

Glioblastoma multiforme (GBM) is an aggressive form of primary brain neoplasm that has a poor[read more]

Antitumor effects of oleandrin in different types of cancers: Systematic review

This article encourages future studies to verify the applicability of oleandrin in antineoplastic therapeutic protocols,[read more]

Efficacy of oleandrin and PBI-05204 against bovine viruses of importance to commercial cattle health

Bovine viral diarrhea virus (BVDV), bovine respiratory syncytial virus (BRSV), and bovine coronavirus (BCV) threaten[read more]

A Role for Cardiac Glycosides in GBM Therapy

Abstract There is a pressing need for new effective therapeutic strategies to treat glioblastoma (GBM).[read more]

“Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1”

Yong L, Ma Y, et al. Phtyother. Res. 2019 May. This article shows that oleandrin[read more]

HTLV-1.

HTLV stands for Human T-cell Leukemia Virus. It is a retrovirus that infects a type[read more]

Because the active principle ingredient in PBI-05204 readily crosses the blood brain barrier (BBB) it has the potential to benefit malignant disease that resides in the brain.

PBI has initiated research on pediatric glioblastoma multiforma (GBM) together with Dr. Xiao-Nan Li (Brain[read more]

PBI is in the process of concluding its Phase II trial of PBI-05204 against advanced, drug refractory pancreatic cancer.

This disease is often diagnosed only after it has metastasized throughout the body making any[read more]

Pharmacokinetics and Comparative Effects of Frondosides in Pancreatic Cancer

by: Jasem Al Shemaili, Khatija Parekh, Robert Newman, Björn Hellman, Carl Woodward, Abdu Adem, Peter[read more]

Research with colleagues at Duke University continues to reveal important brain mediated benefits in response to PBI-05204.

Not only have our two published studies shown an increase in brain derived neurotrophic factor[read more]

Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity.

Singh S, Shenoy S, Nehete PN, Yang P, Nehete B, Fontenot D, Yang G, Newman[read more]

Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes.

Campia I, Sala V, Kopecka J, Leo C, Mitro N, Costamagna C, Caruso D, Pescarmona[read more]

Cellular location and expression of Na+, K+-ATPase α subunits affect the anti-proliferative activity of oleandrin.

Yang, P., Cartwright, C., Efuet, E., Hamilton, S. R., Wistuba, I. I., Menter, D., Addington,[read more]

Research Article: Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.

Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala[read more]

poster presentation along with an oral format with discussion of clinical trial results of PBI-05204.">
ASCO annual meeting poster presentation along with an oral format with discussion of clinical trial results of PBI-05204.

READ MORE

Phoenix Biotechnology executes a third amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Publication: Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug[read more]

Phoenix Biotechnology executes a second amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center.

Publication: Determinants of human and mouse melanoma cell sensitivities to oleandrin. Lin Y, Dubinsky WP,[read more]

THE LATEST NEWS!

Subscribe to our news to get the latest in oleander research!